#Italy #Florence #Implantica #RefluxStop #Careggi Hospital

Implantica's Milestone in GERD Treatment at Careggi University Hospital

Implantica AG, a prominent medtech firm revolutionizing healthcare technology, is making waves in the gastroenterology field with its innovative device, RefluxStop®. This product targets gastroesophageal reflux disease (GERD), a condition impacting approximately one billion individuals globally. Recently, the procedure was successfully conducted at the esteemed Careggi University Hospital in Florence, marking a significant expansion into the European healthcare sector.

The debut operation utilizing RefluxStop® was executed by Dr. Paolo Prosperi, Chief of Emergency Surgery, with the assistance of Dr. Alessio Giordano. Careggi University Hospital, linked with the renowned University of Florence, is recognized for its cutting-edge approaches to surgical technology. The adoption of RefluxStop® at such a prestigious institution signals Implantica's strategic efforts to broaden its reach within major healthcare systems across Europe, paving the way for further implementation of this groundbreaking therapy.

Dr. Prosperi shared his enthusiasm for the innovative advancements in GERD treatment brought about by RefluxStop®. He emphasized that this device presents a significant alternative to traditional anti-reflux surgeries, which typically involve encircling the esophagus, leading to a plethora of adverse effects. The RefluxStop® mechanism, by contrast, does not encircle the esophagus, aiming to restore the natural anti-reflux barrier without inflicting excessive pressure on the food passageway.

Dr. Peter Forsell, the creator of RefluxStop® and CEO of Implantica, congratulated Dr. Prosperi and his team for this landmark achievement. He pointed out that GERD remains a substantial unmet medical challenge, with a significant portion of the Italian population estimated to be affected. Implantica’s ongoing commitment to addressing this medical need has seen over 1,400 RefluxStop® patients treated across Europe, yielding positive results even for those with limited treatment options previously.

This successful launch at Careggi University Hospital is not only a testament to the device's efficacy but also highlights growing clinical confidence within the medical community. Implantica aims to further disseminate RefluxStop® across key healthcare facilities in Europe, enhancing the quality of life for many GERD patients in Tuscany and beyond.

In comparison to conventional anti-reflux surgeries that tend to involve various complications, RefluxStop® offers a unique mechanism of action, reconstructing the anti-reflux barrier and allowing the body to self-manage reflux issues. It establishes a natural anatomical positioning of the lower esophageal sphincter, differentiating it significantly from existing surgical solutions.

With the introduction of RefluxStop®, Implantica is setting a new standard in GERD treatment, aiming to change the lives of countless individuals grappling with this pervasive condition. The support from reputable medical institutions like Careggi University Hospital reinforces the company’s far-reaching vision of transforming surgical treatments through innovation.

Implantica AG calls for continued collaboration with healthcare providers to further improve GERD management strategies and looks forward to the potential impact of RefluxStop® as it expands into more European markets. The company's dedication to enhancing patient outcomes while minimizing surgical risks stands as a pillar of its mission, indicating promising advancements in medical technology for GERD treatments.

In conclusion, Implantica is pioneering a shift in digestive health management, and the successful adoption of RefluxStop® at Careggi University Hospital in Florence marks a significant milestone in making advanced medical technologies accessible to patients in need.